Bristol-Myers Squibb Company Issues Recall For One Lot of Eliquis 5 mg Tablets

Bristol-Myers Squibb Company has issued a consumer-level voluntary recall for one lot (#HN0063) of Eliquis 5 mg tablets because a consumer reported receiving a bottle containing tablets of the wrong dosage. Indicated to reduce the risk of stroke and blood clots in those with atrial fibrillation, the tablets also treat and reduce the risk of blood clots following joint replacement surgeries. The affected lot was distributed nationwide in February 2017, and was recalled as a precautionary measure following a single customer report. Patients should not stop taking Eliquis without consulting with a physician and should contact their provider if they experience any problems. Read the full FDA announcement here.

Clinical Topics: Arrhythmias and Clinical EP, Atrial Fibrillation/Supraventricular Arrhythmias

Keywords: Arthroplasty, Replacement, Atrial Fibrillation, Stroke, Tablets, Thrombosis, United States Food and Drug Administration

< Back to Listings